Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Liver Diseases

  Free Subscription


Articles published in Am J Gastroenterol

Retrieve available abstracts of 135 articles:
HTML format



Single Articles


    September 2025
  1. MAHMUD N, Fricker ZP, McElroy LM, Qayed E, et al
    ACG Clinical Guideline: Perioperative Risk Assessment and Management in Patients With Cirrhosis.
    Am J Gastroenterol. 2025;120:1968-1984.
    PubMed     Abstract available


  2. NIU C, Sun K, Zhang J, Elkhapery A, et al
    Gastrointestinal and Hepatobiliary Safety of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
    Am J Gastroenterol. 2025 Sep 3. doi: 10.14309/ajg.0000000000003760.
    PubMed     Abstract available


    August 2025
  3. JEFFREY AW, Majumdar A, Jeffrey G, Calzadilla-Bertot L, et al
    The Portal Hypertension Decompensation Score - A Validated Predictive Model of Liver Decompensation Related to Portal Hypertension.
    Am J Gastroenterol. 2025 Aug 22. doi: 10.14309/ajg.0000000000003744.
    PubMed     Abstract available


  4. PRAKASH JH, Anirvan P, Gupta S, Chouhan MI, et al
    Diagnostic Accuracy of Spleen-dedicated 100 Hz Transient Elastography to Predict High-risk Esophageal Varices.
    Am J Gastroenterol. 2025 Aug 22. doi: 10.14309/ajg.0000000000003741.
    PubMed     Abstract available


    July 2025
  5. RANA R, Tabish M, Agarwal S, Bayye R, et al
    Simvastatin addition to standard of care improves long-term survival in patients with cirrhosis after variceal bleed: An open label randomized controlled trial.
    Am J Gastroenterol. 2025 Jul 31. doi: 10.14309/ajg.0000000000003689.
    PubMed     Abstract available


  6. OUYANG MM G, Chen Mm X, Yao Mm X, Mo Mm X, et al
    Unprecedented Duodenal Erosion of a Transjugular Intrahepatic Portosystemic Shunt Stent: A Rare Trigger for Recurrent Polymicrobial Sepsis.
    Am J Gastroenterol. 2025 Jul 30. doi: 10.14309/ajg.0000000000003680.
    PubMed    


  7. NGUYEN NV, Sandstrom A, Dominicus A, Mageau A, et al
    Thiopurines and intrahepatic cholestasis of pregnancy in systemic lupus erythematosus and inflammatory bowel disease pregnancies.
    Am J Gastroenterol. 2025 Jul 23. doi: 10.14309/ajg.0000000000003652.
    PubMed     Abstract available


  8. KHAJURIA R, Jindal A, Sharma MK, Arora V, et al
    Efficacy and safety of carvedilol in cirrhosis patients with new-onset uncomplicated ascites without high-risk esophageal varices. (CARVE-AS Trial).
    Am J Gastroenterol. 2025 Jul 21. doi: 10.14309/ajg.0000000000003650.
    PubMed     Abstract available


  9. WOLTSCHE J, Pacher-Deutsch C, Furst S, Gulden L, et al
    Microbial Dysbiosis in the Urinary Microbiome of Patients with Cirrhosis.
    Am J Gastroenterol. 2025 Jul 7. doi: 10.14309/ajg.0000000000003634.
    PubMed     Abstract available


  10. ZHANG K, Zhang L, Zhang J, Lu X, et al
    Unexpected Origin: Gastric Mature Cystic Teratoma Presenting as a Hepatic Mass.
    Am J Gastroenterol. 2025 Jul 2. doi: 10.14309/ajg.0000000000003621.
    PubMed    


    June 2025
  11. CHAPMAN B, Sinclair M, Majumdar A, Yu C, et al
    Real-world experience of home continuous terlipressin infusion for complications of portal hypertension.
    Am J Gastroenterol. 2025 Jun 11. doi: 10.14309/ajg.0000000000003589.
    PubMed     Abstract available


  12. PEREZ-DIAZ-DEL-CAMPO N, Castelnuovo G, Ferro A, Caviglia GP, et al
    Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease and Associated Comorbidities on Cognitive and Health-Related Quality-of-Life Outcomes in a Mixed Metabolic Dysfunction-Associated Steatotic Liver Disease-Type 2 Diabetes Mellitus Cohor
    Am J Gastroenterol. 2025;120:1779-1790.
    PubMed     Abstract available


  13. SOGBE M, Wong R, Bloomer PM, Steinberg A, et al
    Psychomotor speed from minimal hepatic encephalopathy testing is associated with physical frailty in patients with advanced chronic liver disease.
    Am J Gastroenterol. 2025 Jun 9. doi: 10.14309/ajg.0000000000003583.
    PubMed     Abstract available


    May 2025
  14. DESAI AP, Scherer AN, Serper M
    The Role of Patient-Reported Outcomes in Cirrhosis.
    Am J Gastroenterol. 2025 May 20. doi: 10.14309/ajg.0000000000003551.
    PubMed     Abstract available


  15. HWANG SY, Rezaee-Zavareh MS, Attia AM, Kaymen EA, et al
    Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Am J Gastroenterol. 2025 May 16. doi: 10.14309/ajg.0000000000003546.
    PubMed     Abstract available


  16. SOUZA M, Al-Sharif L, Diaz I, Khalil SM, et al
    Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates.
    Am J Gastroenterol. 2025 May 5. doi: 10.14309/ajg.0000000000003520.
    PubMed     Abstract available


  17. SINGAL AK, Wong RJ, Dasarathy S, Abdelmalek MF, et al
    ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease.
    Am J Gastroenterol. 2025;120:950-972.
    PubMed     Abstract available


  18. THOMAS A
    Continuing Medical Education Questions: May 2025.
    Am J Gastroenterol. 2025;120:948.
    PubMed     Abstract available


    April 2025
  19. WALKER T, Alejandro-Soto A, Nephew L, Jones P, et al
    Association of Social Isolation From Living Alone and Psychological Distress Among Adults With Chronic Liver Disease in the United States.
    Am J Gastroenterol. 2025;120:1860-1864.
    PubMed     Abstract available


  20. SINGAL AG, Yang JD, Jalal PK, Salgia R, et al
    Patient-Perceived Risk of Hepatocellular Carcinoma and Net Benefit of Surveillance: A Multicenter Survey Study.
    Am J Gastroenterol. 2025;120:1800-1808.
    PubMed     Abstract available


  21. MOON AM, Lupu GV, Green EW, Deutsch-Link S, et al
    Rural-urban disparities in hepatocellular carcinoma deaths are driven by hepatitis C-related HCC.
    Am J Gastroenterol. 2025 Apr 11. doi: 10.14309/ajg.0000000000003487.
    PubMed     Abstract available


  22. KUMAR A, Arora A, Choudhury A, Arora V, et al
    Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease-Related Acute-on-Chronic Liver Failure.
    Am J Gastroenterol. 2025;120:816-826.
    PubMed     Abstract available


    March 2025
  23. GARRIDO-TREVINO L, Ahn S, Tapper EB, Walker OC, et al
    Diagnosis of Acute on Chronic Liver Failure in critically ill patients with cirrhosis using administrative data.
    Am J Gastroenterol. 2025 Mar 17. doi: 10.14309/ajg.0000000000003422.
    PubMed     Abstract available


    February 2025
  24. CHOLANKERIL G, Taylor T, Kramer JR, Liu Y, et al
    Inequalities in developing cirrhosis complications over time: A cohort study.
    Am J Gastroenterol. 2025 Feb 5. doi: 10.14309/ajg.0000000000003354.
    PubMed     Abstract available


  25. YUN B, Park H, Ahn SH, Oh J, et al
    Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.
    Am J Gastroenterol. 2025;120:410-419.
    PubMed     Abstract available


    January 2025
  26. DECHARATANACHART P, Poovorawan K, Tangkijvanich P, Charatcharoenwitthaya P, et al
    Cost-Utility Analysis of Non-Invasive Tests to Initiate Hepatocellular Carcinoma Surveillance in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Am J Gastroenterol. 2025 Jan 29. doi: 10.14309/ajg.0000000000003332.
    PubMed     Abstract available


  27. ROMAIN D, Hao S, Grzyb K, Bashaw L, et al
    Electronic Interventions to Improve Quality for Inpatient Cirrhosis Care: a prospective evaluation.
    Am J Gastroenterol. 2025 Jan 29. doi: 10.14309/ajg.0000000000003334.
    PubMed     Abstract available


  28. GHANDOUR B, Kaplan DE, Mahmud N
    High Cirrhosis Surgical Volume Centers have Reduced Postoperative Mortality in Patients with Cirrhosis Undergoing Major Surgery.
    Am J Gastroenterol. 2025 Jan 21. doi: 10.14309/ajg.0000000000003329.
    PubMed     Abstract available


  29. MORITA M, Takita M, Nishida N, Kudo M, et al
    Giant Sister Mary Joseph;s nodule in Hepatocellular Carcinoma.
    Am J Gastroenterol. 2025 Jan 17. doi: 10.14309/ajg.0000000000003325.
    PubMed    


  30. SILVEY S, Patel N, O'Leary JG, Bajaj JS, et al
    ENHANCEMENT OF CIRRHOSIS MORTALITY PREDICTION BY INCLUDING HEPATIC ENCEPHALOPATHY TO MELD3.0 IN A NATIONAL VETERAN COHORT.
    Am J Gastroenterol. 2025 Jan 16. doi: 10.14309/ajg.0000000000003317.
    PubMed     Abstract available


  31. BERAN A, Elfert K, Patel FN, Mohamed M, et al
    Risk of Post-polypectomy Bleeding After Colorectal Endoscopic Mucosal Resection in Patients With Cirrhosis: A Propensity-Matched Analysis of the US Collaborative Network.
    Am J Gastroenterol. 2025 Jan 16. doi: 10.14309/ajg.0000000000003322.
    PubMed     Abstract available


  32. WONG F, Vagas HE, Reddy KR, Pagadala MR, et al
    The Effects of alfapump on Ascites Control and Quality of Life in Patients with Cirrhosis and Recurrent or Refractory Ascites.
    Am J Gastroenterol. 2025 Jan 6. doi: 10.14309/ajg.0000000000003300.
    PubMed     Abstract available


    December 2024
  33. QIAO Y, Yang L, Yang H, Zheng M, et al
    Longitudinal Associations Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Subclinical Cardiovascular Measures in Chinese Children.
    Am J Gastroenterol. 2024;120:1395-1399.
    PubMed     Abstract available


  34. SINGAL AK, Pannerselvam D, Arab JP, Im G, et al
    Delisting From Liver Transplant List for Improvement and Re-compensation Among Decompensated Patients at one-year.
    Am J Gastroenterol. 2024 Dec 23. doi: 10.14309/ajg.0000000000003259.
    PubMed     Abstract available


  35. MALIK S, Frey LJ, Gutman J, Mushtaq A, et al
    Evaluating Artificial Intelligence-Driven Responses to Acute Liver Failure Queries: A Comparative Analysis Across Accuracy, Clarity, and Relevance.
    Am J Gastroenterol. 2024;120:2081-2085.
    PubMed     Abstract available


  36. LEDENKO M, Patel T
    Poverty Traps and Mortality From Liver Diseases in the United States.
    Am J Gastroenterol. 2024;119:2462-2470.
    PubMed     Abstract available


    November 2024
  37. WONG F, Reddy KR, Tandon P, Lai JC, et al
    Sex differences in patient-reported outcomes and perception of ascites burden amongst outpatients with decompensated cirrhosis and ascites.: Sex Differences in Ascites Burden Perception.
    Am J Gastroenterol. 2024 Nov 27. doi: 10.14309/ajg.0000000000003251.
    PubMed     Abstract available


  38. PACHISIA AV, Agarwal A, Mehta S, Kumari A, et al
    Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet.
    Am J Gastroenterol. 2024 Nov 26. doi: 10.14309/ajg.0000000000003244.
    PubMed     Abstract available


  39. SHAH N, Sanyal AJ
    A PRAGMATIC MANAGEMENT APPROACH FOR METABOLIC DYSFUNCTION ASSOCIATED STEATOSIS AND STEATOHEPATITIS.
    Am J Gastroenterol. 2024 Nov 21. doi: 10.14309/ajg.0000000000003215.
    PubMed    


  40. NIE C, Vaska M, Wong JK, Bathe OF, et al
    Tumor Seeding With Needle Biopsy of Hepatocellular Carcinoma: A Systematic Review.
    Am J Gastroenterol. 2024 Nov 14. doi: 10.14309/ajg.0000000000003210.
    PubMed     Abstract available


  41. LAURENZANO J, Ganesan P, Harrington C, Slaughter JC, et al
    Post-Transjugular Intrahepatic Portosystemic Shunt Right Atrial Pressure and Left Atrial Volume Index Predict Heart Failure and Mortality: Dual Center Experience.
    Am J Gastroenterol. 2024 Nov 14. doi: 10.14309/ajg.0000000000003211.
    PubMed     Abstract available


  42. HUANG Y, Huang H, Wei T, Zhang A, et al
    Disparities, Trends, and Predictions to 2040 in Gastrointestinal Cancer Incidence, Mortality in the United States.
    Am J Gastroenterol. 2024;120:1367-1380.
    PubMed     Abstract available


  43. SERPER M, Pulaski ME, Zhang S, Taddei TH, et al
    Albumin for Spontaneous Bacterial Peritonitis: Care Variation, Disparities, and Outcomes.
    Am J Gastroenterol. 2024;120:2059-2071.
    PubMed     Abstract available


  44. BATHEJA MA
    Continuing Medical Education Questions: November 2024.
    Am J Gastroenterol. 2024;119:2172.
    PubMed     Abstract available


  45. SINGAL AG, Parikh ND, Shetty K, Han SH, et al
    Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study.
    Am J Gastroenterol. 2024;119:2251-2258.
    PubMed     Abstract available


    October 2024
  46. BHUSHAN S, Sohal A, Kowdley KV, Agaf FF, et al
    Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape.
    Am J Gastroenterol. 2024 Oct 31. doi: 10.14309/ajg.0000000000003174.
    PubMed     Abstract available


  47. MURNANE PM, Afshar M, Chamie G, Cook RL, et al
    Using Phosphatidylethanol as an Adjunct to Self-Reported Alcohol Use Improves Identification of Liver Fibrosis Risk.
    Am J Gastroenterol. 2024;120:1567-1575.
    PubMed     Abstract available


  48. CHEN VL, Oliveri A, Raut C, Chen Y, et al
    TM6SF2-rs58542926 genotype has opposing effects on incidence of hepatic and cardiac events in a community cohort: TM6SF2 effects on liver and cardiac outcomes.
    Am J Gastroenterol. 2024 Oct 30. doi: 10.14309/ajg.0000000000003169.
    PubMed     Abstract available


  49. HASJIM BJ, Harris A, Balbale SN, Obayemi JE, et al
    Social Disadvantage and Disparities in Chronic Liver Disease: A Systematic Review.
    Am J Gastroenterol. 2024;120:1548-1566.
    PubMed     Abstract available


  50. KIM NJ, Vutien P, Borgerding JA, Beste LA, et al
    Hepatic steatosis estimated by VCTE-derived CAP scores was associated with lower risks of liver-related events and all-cause mortality in patients with chronic liver disease.
    Am J Gastroenterol. 2024 Oct 25. doi: 10.14309/ajg.0000000000003161.
    PubMed     Abstract available


  51. UFERE NN, Zeng C, Donlan J, Shalev D, et al
    Psychological Distress is Prevalent and Interdependent Among Patients with Decompensated Cirrhosis and Their Caregivers.
    Am J Gastroenterol. 2024 Oct 25. doi: 10.14309/ajg.0000000000003158.
    PubMed     Abstract available


  52. MOON AM
    Raising the Bar: Is Hepatocellular Carcinoma Surveillance Warranted for Patients With Alcohol-Associated Cirrhosis?
    Am J Gastroenterol. 2024 Oct 24. doi: 10.14309/ajg.0000000000003123.
    PubMed    


  53. BARRITT AS 4TH, Hayashi PH, Stolz AA, Barnhart H, et al
    Refinement of Hy Law Using the Drug-Induced Liver Injury Network Database.
    Am J Gastroenterol. 2024;120:1307-1313.
    PubMed     Abstract available


  54. CIRICILLO J, Myer A, Yeboah-Korang A, Osman A, et al
    Improving the Diagnostic Accuracy of RECAM in North American Patients With Suspected Idiosyncratic Drug-Induced Liver Injury.
    Am J Gastroenterol. 2024;120:1325-1333.
    PubMed     Abstract available


  55. JM E, E V, Nm I
    Predicting and preventing bleeding in patients with cirrhosis undergoing procedures.
    Am J Gastroenterol. 2024 Oct 9. doi: 10.14309/ajg.0000000000003129.
    PubMed    


  56. VERMA N, Roy A, Valsan A, Garg P, et al
    Liver Dysfunction and Systemic Inflammation Drive Organ Failures in Acute Decompensation of Cirrhosis: A Multi-Centric Study.
    Am J Gastroenterol. 2024 Oct 4. doi: 10.14309/ajg.0000000000003115.
    PubMed     Abstract available


  57. LANZ-ZUBIRIA L, Chavez-Tapia NC
    To Continue or Discontinue beta-Blockers in Secondary Prophylaxis? That is the Dilemma.
    Am J Gastroenterol. 2024;119:2143.
    PubMed    


  58. TANAKA T, Vander Weg M, Jones MP, Wehby G, et al
    Assessment of the 2021 AASLD Practice Guidance for Albumin Infusion in Elective Therapeutic Paracentesis: A Regression Discontinuity Design.
    Am J Gastroenterol. 2024;119:2045-2051.
    PubMed     Abstract available


  59. ZAVER HB, Rajpal N, Shah NL, Argo CK, et al
    MELD and MELD 3.0: What It Means for Your Practice.
    Am J Gastroenterol. 2024;119:1951-1954.
    PubMed    


    September 2024
  60. JUTRAS G, Flemming JA
    Global Epidemiology of Cirrhosis in Women.
    Am J Gastroenterol. 2024 Sep 19. doi: 10.14309/ajg.0000000000003086.
    PubMed     Abstract available


  61. JENSEN MD, West PJ, Crooks C, Morling JR, et al
    Primary liver cancer risk and mortality in patients with alcohol-related cirrhosis in England and Denmark: observational cohort studies.
    Am J Gastroenterol. 2024 Sep 9. doi: 10.14309/ajg.0000000000003077.
    PubMed     Abstract available


  62. SILVEY S, Patel NR, Tsai SY, Nadeem M, et al
    Higher Rate of SBP Recurrence with Secondary SBP Prophylaxis Compared to No Prophylaxis in Two National Cirrhosis Cohorts.
    Am J Gastroenterol. 2024 Sep 4. doi: 10.14309/ajg.0000000000003075.
    PubMed     Abstract available


  63. WONG RJ, Yang Z, Yeoh A, Do A, et al
    Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Am J Gastroenterol. 2024;119:1841-1848.
    PubMed     Abstract available


    August 2024
  64. KRONSTEN VT, Shawcross DL
    Clinical implications of inflammation in patients with cirrhosis.
    Am J Gastroenterol. 2024 Aug 27. doi: 10.14309/ajg.0000000000003056.
    PubMed     Abstract available


  65. KOWDLEY KV, Hirschfield GM, Coombs C, Malecha ES, et al
    COBALT: A Confirmatory Trial of Obeticholic Acid in Primary Biliary Cholangitis With Placebo and External Controls.
    Am J Gastroenterol. 2024 Aug 14. doi: 10.14309/ajg.0000000000003029.
    PubMed     Abstract available


  66. LI M, Shu W, Zou Y, Xiao H, et al
    Reversing Metabolic Dysfunction-Associated Steatotic Liver Disease Promotes Healthy Pediatric Cardiovascular Structures: The PROC Study.
    Am J Gastroenterol. 2024;119:1640-1643.
    PubMed     Abstract available


  67. BARRITT AS 4TH, Yu F, Mospan AR, Newsome PN, et al
    High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.
    Am J Gastroenterol. 2024;119:1624-1627.
    PubMed     Abstract available


  68. VANDERSCHUEREN E, Armandi A, Kwanten W, Cassiman D, et al
    Spleen Stiffness-Based Algorithms Are Superior to Baveno VI Criteria to Rule Out Varices Needing Treatment in Patients With Advanced Chronic Liver Disease.
    Am J Gastroenterol. 2024;119:1515-1524.
    PubMed     Abstract available


  69. STERLING RK, Vilar-Gomez E, Wilson LA, Loomba R, et al
    Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living With HIV and Steatotic Liver Disease.
    Am J Gastroenterol. 2024;119:1483-1495.
    PubMed     Abstract available


  70. FONTANA RJ, Li YJ, Vuppalanchi R, Kleiner DE, et al
    ERAP-1 and ERAP-2 Variants in Liver Injury After COVID-19 mRNA Vaccination: A US Multicenter Study.
    Am J Gastroenterol. 2024;119:1496-1505.
    PubMed     Abstract available


  71. LIU C, Cao Z, Yan H, Wong YJ, et al
    Correction to: A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study.
    Am J Gastroenterol. 2024;119:1706.
    PubMed    


    July 2024
  72. WANG RX, Serper M, Taddei TH, Kaplan DE, et al
    The Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Exposure and Key Cirrhosis-Related Outcomes.
    Am J Gastroenterol. 2024 Jul 25. doi: 10.14309/ajg.0000000000002976.
    PubMed     Abstract available


  73. SHENOY A, Valicevic AN, Lin A, Su GL, et al
    Delivery of Outpatient Cirrhosis Care Via Tele-visit is Not Associated with Increased Mortality as Compared to Traditional In-Person Visits.
    Am J Gastroenterol. 2024 Jul 25. doi: 10.14309/ajg.0000000000002979.
    PubMed     Abstract available


  74. TAPPER EB, Goldberg D, Parikh ND, Terrault NA, et al
    The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints.
    Am J Gastroenterol. 2024 Jul 17. doi: 10.14309/ajg.0000000000002953.
    PubMed     Abstract available


  75. KAZUMORI H, Saima A, Ohno Y
    Development of Giant Hepatocellular Carcinoma Leads to Biliary Plastic Stent Compression Resulting in Pseudoaneurysm Rupture in Right Hepatic Artery.
    Am J Gastroenterol. 2024 Jul 8. doi: 10.14309/ajg.0000000000002938.
    PubMed    


  76. ARTZNER T, Goldberg DS, Sundaram V, Faitot F, et al
    Improvement in survival after transplantation for critically ill patients with cirrhosis in the United States.
    Am J Gastroenterol. 2024 Jul 5. doi: 10.14309/ajg.0000000000002944.
    PubMed     Abstract available


  77. LOUISSAINT J, Kyalwazi B, Deng J, Melendez-Torres J, et al
    Patients With Cirrhosis Rapidly Review Potentially Abnormal Hepatocellular Carcinoma Surveillance Results Through the Patient Portal.
    Am J Gastroenterol. 2024 Jul 3. doi: 10.14309/ajg.0000000000002940.
    PubMed     Abstract available


  78. FRENETTE C, Mendiratta-Lala M, Salgia R, Wong RJ, et al
    ACG Clinical Guideline: Focal Liver Lesions.
    Am J Gastroenterol. 2024;119:1235-1271.
    PubMed     Abstract available


  79. ASKGAARD G, Jepsen P, Jensen MD, Kann AE, et al
    Population-Based Study of Alcohol-Related Liver Disease in England in 2001-2018: Influence of Socioeconomic Position.
    Am J Gastroenterol. 2024;119:1337-1345.
    PubMed     Abstract available


    June 2024
  80. HUANG SC, Su TH, Tseng TC, Liao SH, et al
    Pre-existing and new-onset metabolic dysfunctions increase cirrhosis and its complication risks in chronic hepatitis B.
    Am J Gastroenterol. 2024 Jun 26. doi: 10.14309/ajg.0000000000002915.
    PubMed     Abstract available


  81. BERAN A, Mohamed MFH, Vargas A, Aboursheid T, et al
    Early Diagnostic Paracentesis Improves Outcomes of Hospitalized Patients with Cirrhosis and Ascites: A Systematic Review and Meta-Analysis.
    Am J Gastroenterol. 2024 Jun 25. doi: 10.14309/ajg.0000000000002906.
    PubMed     Abstract available


  82. ELHENCE H, Dodge JL, Kahn JA, Lee BP, et al
    Characteristics and Outcomes Among U.S. Commercially Insured Transgender Adults with Cirrhosis: A National Cohort Study.
    Am J Gastroenterol. 2024 Jun 25. doi: 10.14309/ajg.0000000000002907.
    PubMed     Abstract available


  83. PARVATANENI S, Sarkis Y, Haugh M, Baker B, et al
    A comprehensive evaluation of emergency department utilization by patients with cirrhosis.
    Am J Gastroenterol. 2024 Jun 24. doi: 10.14309/ajg.0000000000002905.
    PubMed     Abstract available


  84. THABUT D, Rudler M, Weiss N
    Diagnosis of Overt Hepatic Encephalopathy With a New Algorithm: Follow-up Data Are Required.
    Am J Gastroenterol. 2024 Jun 3. doi: 10.14309/ajg.0000000000002856.
    PubMed    


  85. PAIK JM, Duong S, Zelber-Sagi S, Lazarus JV, et al
    Food Insecurity, Low Household Income, and Low Education Level Increase the Risk of Having Metabolic Dysfunction-Associated Fatty Liver Disease Among Adolescents in the United States.
    Am J Gastroenterol. 2024;119:1089-1101.
    PubMed     Abstract available


    May 2024
  86. DANPANICHKUL P, Ng CH, Muthiah M, Suparan K, et al
    From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women.
    Am J Gastroenterol. 2024;119:893-909.
    PubMed     Abstract available


    April 2024
  87. BAJAJ JS, Pimentel M
    Is Hepatic Encephalopathy the First True Disorder of Gut-Brain interaction?
    Am J Gastroenterol. 2024 Apr 22. doi: 10.14309/ajg.0000000000002824.
    PubMed    


  88. HUME SJ, Holmes JA, Thompson AJ
    Individualizing the Approach to Stopping Nucleos(t)ide Analogs: Can We Use a Low HBsAg Threshold to Predict a High Chance of Functional Cure and Minimal Risk of Hepatic Decompensation?
    Am J Gastroenterol. 2024 Apr 15. doi: 10.14309/ajg.0000000000002766.
    PubMed    


  89. ERMINELLI D, Mangini C, Zarantonello L, Angeli P, et al
    Overt hepatic encephalopathy - more than meets the eye.
    Am J Gastroenterol. 2024 Apr 8. doi: 10.14309/ajg.0000000000002795.
    PubMed     Abstract available


  90. KHANNA S, Shah NL, Argo CK
    Use of Phosphatidylethanol Testing in Patients With Liver Disease.
    Am J Gastroenterol. 2024;119:596-599.
    PubMed    


  91. PERUMALSWAMI PV, Winder GS, Fernandez AC, Mellinger JL, et al
    Practical Considerations to Optimize Care for Patients With Alcohol-Associated Liver Disease in General Gastroenterology Practice.
    Am J Gastroenterol. 2024;119:591-595.
    PubMed    


    March 2024
  92. CHEN YT, Chen TI, Yang TH, Yin SC, et al
    Long-term Risks for Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes.
    Am J Gastroenterol. 2024 Mar 27. doi: 10.14309/ajg.0000000000002778.
    PubMed     Abstract available


  93. CHEN QF, Chen S, Yi JZ, Wang JL, et al
    Recommended Ten Years' Follow-Up Strategy for Small Hepatocellular Carcinoma after Radiofrequency Ablation: A Cost-Effectiveness Evaluation.
    Am J Gastroenterol. 2024 Mar 25. doi: 10.14309/ajg.0000000000002774.
    PubMed     Abstract available


  94. LO GH, Yeh JH, Tseng CH, Chen TH, et al
    A non-inferiority trial comparing 2 days vs. 5 days of terlipressin and ceftriaxone in terms of 5-day rebleeding for patients with acute gastro-esophageal variceal hemorrhage.
    Am J Gastroenterol. 2024 Mar 25. doi: 10.14309/ajg.0000000000002776.
    PubMed     Abstract available


  95. TABISH M, Agarwal S, Gopi S, Rana R, et al
    Randomized controlled trial of Intravenous ferric-carboxymaltose vs oral iron to treat iron deficiency anemia after variceal bleed in patients with cirrhosis.
    Am J Gastroenterol. 2024 Mar 22. doi: 10.14309/ajg.0000000000002775.
    PubMed     Abstract available


  96. SAMALA N, Xin Y, Wilson LA, Yates K, et al
    Non-Hispanic Black persons with nonalcoholic fatty liver disease have lower rates of advanced fibrosis, cirrhosis, and liver-related events even after controlling for clinical risk factors and PNPLA3 genotype.
    Am J Gastroenterol. 2024 Mar 14. doi: 10.14309/ajg.0000000000002756.
    PubMed     Abstract available


  97. HIRODE G, Hansen BE, Chen CH, Su TH, et al
    Erratum: Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).
    Am J Gastroenterol. 2024 Mar 8. doi: 10.14309/ajg.0000000000002718.
    PubMed    


  98. ZHANG X, Daniel CR, Soltero V, Vargas X, et al
    A Study of Dietary Patterns Derived by Cluster Analysis and Their Association With Metabolic Dysfunction-Associated Steatotic Liver Disease Severity Among Hispanic Patients.
    Am J Gastroenterol. 2024;119:505-511.
    PubMed     Abstract available


    February 2024
  99. SASAKI S, Schmidt S, Uldry E, Halkic N, et al
    Hepaticocholecystic Duct: Not a Myth but a Pitfall in Cholecystectomy.
    Am J Gastroenterol. 2024 Feb 19. doi: 10.14309/ajg.0000000000002725.
    PubMed    


  100. LOUISSAINT J, Vargas HE
    Picture Perfect: Artificial Intelligence in the Management of Hepatic Encephalopathy.
    Am J Gastroenterol. 2024 Feb 16. doi: 10.14309/ajg.0000000000002659.
    PubMed    


  101. BUI H, Kumar NG, Singal AG, Boparai J, et al
    Implementation of a hepatocellular carcinoma surveillance program in a community-based integrated health system in patients with hepatitis C cirrhosis.
    Am J Gastroenterol. 2024 Feb 9. doi: 10.14309/ajg.0000000000002704.
    PubMed     Abstract available


  102. RANGRAY R
    Continuing Medical Education Questions: February 2024.
    Am J Gastroenterol. 2024;119:248.
    PubMed     Abstract available


  103. BATHEJA MA
    Continuing Medical Education Questions: February 2024.
    Am J Gastroenterol. 2024;119:247.
    PubMed     Abstract available


  104. MURPHY CC, Tavakkoli A, Wani S, Singal AG, et al
    Pandemic-Related Changes in Incidence and Mortality Rates of Gastrointestinal Cancers During 2020.
    Am J Gastroenterol. 2024;119:382-387.
    PubMed     Abstract available


  105. JULIEN J, Ayer T, Tapper EB, Chhatwal J, et al
    The Rising Costs of Alcohol-Associated Liver Disease in the United States.
    Am J Gastroenterol. 2024;119:270-277.
    PubMed     Abstract available


    January 2024
  106. GE J, Chen IY, Pletcher MJ, Lai JC, et al
    How I Approach It: Prompt Engineering for Generative Artificial Intelligence (GAI) in Gastroenterology and Hepatology.
    Am J Gastroenterol. 2024 Jan 31. doi: 10.14309/ajg.0000000000002689.
    PubMed    


  107. CHARA BS, Hara KS, Penrice D, Schmidt KA, et al
    ARTIFICIAL INTELLIGENCE-ENABLED STOOL ANALYSIS FOR LACTULOSE TITRATION ASSISTANCE IN HEPATIC ENCEPHALOPATHY VIA A SMARTPHONE APPLICATION.
    Am J Gastroenterol. 2024 Jan 19. doi: 10.14309/ajg.0000000000002656.
    PubMed     Abstract available


  108. BLOOM PP, Bajaj JS
    The Current and Future State of Microbiome Therapeutics in Liver Disease.
    Am J Gastroenterol. 2024;119.
    PubMed    


  109. KARNA R
    Continuing Medical Education Questions: January 2024.
    Am J Gastroenterol. 2024;119:27.
    PubMed     Abstract available


  110. NICOLETTI P, Dellinger A, Li YJ, Barnhart H, et al
    HLA-B*53:01 Is a Significant Risk Factor of Liver Injury due to Phenytoin and Other Antiepileptic Drugs in African Americans.
    Am J Gastroenterol. 2024;119:200-202.
    PubMed     Abstract available


    December 2023
  111. FAGAN A, Gallagher ML, Mousel T, Davis BC, et al
    AI evaluation of Stool Quality Guides Management of Hepatic Encephalopathy using a Smartphone App.
    Am J Gastroenterol. 2023 Dec 28. doi: 10.14309/ajg.0000000000002646.
    PubMed     Abstract available


  112. MUI BG, Grinspan LT, Crismale JF
    Variations in practice among cirrhotic patients with portal vein thrombosis and esophageal varices: a North American survey study.
    Am J Gastroenterol. 2023 Dec 26. doi: 10.14309/ajg.0000000000002640.
    PubMed     Abstract available


  113. MULGAONKAR A, Huang DQ, Siddiqi H, Fowler K, et al
    Cost-Effectiveness Analysis of HCC Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis using US Visualization Score C-Triggered Abbreviated MRI.
    Am J Gastroenterol. 2023 Dec 26. doi: 10.14309/ajg.0000000000002636.
    PubMed     Abstract available


  114. PRICE JC, Springer G, Seaberg EC, Budoff MJ, et al
    High incidence rate of CT-measured steatotic liver disease in men with and without HIV infection.
    Am J Gastroenterol. 2023 Dec 22. doi: 10.14309/ajg.0000000000002633.
    PubMed     Abstract available


  115. LEE JD, Gounko D, Lee JA, Mukherjee T, et al
    Assisted Reproductive Technology Treatment Outcomes in Women With Liver Disease.
    Am J Gastroenterol. 2023;118:2184-2190.
    PubMed     Abstract available


    November 2023
  116. DAHER D, El Dahan KS, Yekkaluri S, Gopal P, et al
    Proportion Time Covered by Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
    Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002596.
    PubMed     Abstract available


  117. HASHMI I, Chadha N, McIntosh G, Sterling R, et al
    Quality Improvement for Health Care Providers in Gastroenterology and Hepatology.
    Am J Gastroenterol. 2023 Nov 17. doi: 10.14309/ajg.0000000000002609.
    PubMed    


  118. KULKARNI AV, Avadhanam M, Karandikar P, Rakam K, et al
    Antibiotics with or without Rifaximin for acute hepatic Encephalopathy in critically ill patients with cirrhosis: A double-blind, randomized controlled (ARiE) trial.
    Am J Gastroenterol. 2023 Nov 9. doi: 10.14309/ajg.0000000000002575.
    PubMed     Abstract available


  119. BAJAJ JS, Kamath PS, Reddy KR, Asrani SK, et al
    Predictors of Respiratory Failure Development in A Multi-Center Cohort of Inpatients with Cirrhosis.
    Am J Gastroenterol. 2023 Nov 8. doi: 10.14309/ajg.0000000000002574.
    PubMed     Abstract available


  120. PATEL A, Bowman CA, Prause N, Kilaru SM, et al
    Outcomes of a Three-Year Quality Improvement Study to Improve Advance Care Planning in Patients with Decompensated Cirrhosis.
    Am J Gastroenterol. 2023 Nov 7. doi: 10.14309/ajg.0000000000002570.
    PubMed     Abstract available


  121. WANG B, Zhou J, Wu X, Sun Y, et al
    Carvedilol plus NUCs for compensated HBV-cirrhosis patients under virological suppression: a randomised, open-label trial.
    Am J Gastroenterol. 2023 Nov 6. doi: 10.14309/ajg.0000000000002569.
    PubMed     Abstract available


  122. YAGHOOBI M
    Continuing Medical Education Questions: November 2023.
    Am J Gastroenterol. 2023;118:1925.
    PubMed     Abstract available


  123. KIM J, Zhang Y, Kim H, Zhang Y, et al
    A Comparative Study of Healthy Dietary Patterns for Incident and Fatal Digestive System Cancer.
    Am J Gastroenterol. 2023;118:2061-2070.
    PubMed     Abstract available


  124. SQUIZZATO F, Abruzzino G, Piazza M
    Acute Liver Failure in a Patient With Previous Vascular Surgery for Bowel Ischemia.
    Am J Gastroenterol. 2023;118:1919.
    PubMed    


  125. CHO Y, Chang Y, Ryu S, Kim C, et al
    History of Gestational Diabetes and Incident Nonalcoholic Fatty Liver Disease: The Kangbuk Samsung Health Study.
    Am J Gastroenterol. 2023;118:1980-1988.
    PubMed     Abstract available


    October 2023
  126. LV XH, Lu Q, Deng K, Yang JL, et al
    Prevalence and characteristics of covert/minimal hepatic encephalopathy in patients with liver cirrhosis: A systematic review and meta-analysis.
    Am J Gastroenterol. 2023 Oct 19. doi: 10.14309/ajg.0000000000002563.
    PubMed     Abstract available


  127. SILKE L, Donata G, Dominik G, Uli F, et al
    Endoscopic features of post-COVID-19 cholangiopathy and its management using ERCP.
    Am J Gastroenterol. 2023 Oct 16. doi: 10.14309/ajg.0000000000002562.
    PubMed     Abstract available


  128. OZTURK NB, Jamil LH, Tapper EB
    Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients with Cirrhosis.
    Am J Gastroenterol. 2023 Oct 13. doi: 10.14309/ajg.0000000000002560.
    PubMed     Abstract available


  129. PRASOPPOKAKORN T, Panarat P
    Disseminated Melioidosis infection involving hepatosplenomegaly and massive extramedullary hematopoiesis.
    Am J Gastroenterol. 2023 Oct 4. doi: 10.14309/ajg.0000000000002549.
    PubMed    


  130. PULASKI M, Bittermann T, Taddei TH, Kaplan DE, et al
    The Association between Homelessness and Key Liver-Related Outcomes in Veterans with Cirrhosis.
    Am J Gastroenterol. 2023 Oct 2. doi: 10.14309/ajg.0000000000002535.
    PubMed     Abstract available


  131. ONG J, Mandour MO, Allison M
    Endoscopic Gastric Plication in Nonalcoholic Fatty Liver Disease.
    Am J Gastroenterol. 2023;118:1899.
    PubMed    


    September 2023
  132. NACHEF C, Bousson V, Belmatoug N, Cohen-Solal M, et al
    Osteoporosis and fragility fractures in patients with cirrhosis evaluated for liver transplantation: Identification of high-risk patients based on computed tomography at evaluation.
    Am J Gastroenterol. 2023 Sep 20. doi: 10.14309/ajg.0000000000002507.
    PubMed     Abstract available


  133. FENG X, Li H, Bajaj J, Moon AM, et al
    Endoscopic Ultrasound (EUS)-guided Sclerotherapy with Lauromacrogol: A Novel Therapy for A Giant Esophageal Hemangioma.
    Am J Gastroenterol. 2023 Sep 20. doi: 10.14309/ajg.0000000000002514.
    PubMed    


    July 2023
  134. LARINO-NOIA J, Fernandez-Castroagudin J, de la Iglesia-Garcia D, Lazare H, et al
    Quality of Tissue Samples Obtained by Endoscopic Ultrasound-Guided Liver Biopsy: A Randomized, Controlled Clinical Trial.
    Am J Gastroenterol. 2023 Jul 14. doi: 10.14309/ajg.0000000000002375.
    PubMed     Abstract available


    March 2023
  135. LIU Y, Guo G, Zheng L, Sun R, et al
    Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: A Randomized Clinical Trial.
    Am J Gastroenterol. 2023 Mar 9. doi: 10.14309/ajg.0000000000002238.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.